Sysmex Corporation (シスメックス株式会社, Shisumekkusu Kabushiki-gaisha) is a Japanese company headquartered in Kobe that is engaged in the health care business. Originally called TOA Medical Electronics (a branch of the TOA Corporation), the Sysmex brand was established in 1978, and were mainly involved with haematology analysers. The company was renamed Sysmex Corporation in 1998 taking advantage of brand recognition of their machines.
Second-line FOLFIRI plus ramucirumab (RAM) is one of standard treatments for metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy in RAS wild-type tumors. However, biomarkers for RAM efficacy remain unclear. We conducted a translational analysis to evaluate the association of plasma biomarkers, including angiogenesis-related factors (AFs) and RAS mutations in circulating tumor DNA (ctDNA), with clinical outcomes. This biomarker study was embedded within the JACCRO CC-16 trial, which enrolled patients with mCRC with RAS wild-type tumors receiving FOLFIRI plus RAM after anti-EGFR therapy. Plasma samples were collected at baseline, day 15, and post-treatment. RAS status in ctDNA was analyzed using BEAMing digital PCR; AFs were assessed using Luminex multiplex assay. Associations with progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analyzed. Among 41 evaluable patients with RAS wild-type tumors, RAS mutations were detected in ctDNA at pretreatment in 44
Background:The chemokine CXCL9, induced by interferon-γ (IFN-γ), is a hallmark of type 1 (T1) inflammation. Its role in chronic respiratory diseases remains unclear, with conflicting evidence suggesting it may reflect steroid-responsive inflammation in interstitial lung disease (ILD) but correlate with worse function in chronic obstructive pulmonary disease (COPD). Methods:Serum levels of CXCL9, KL-6, SP-A, and CRP were measured in 83 ILD patients (with paired samples before and after treatment), 94 COPD patients, and 100 healthy controls (50 smokers and 50 non-smokers). Lung function and biomarker correlations were analyzed, and unsupervised cluster analysis was used to explore inflammatory phenotypes. Results:CXCL9 levels were markedly elevated in both ILD (median: 57.4 pg/mL) and COPD (70.1 pg/mL) compared to healthy smokers (32.5 pg/mL) and non-smokers (37.0 pg/mL). In COPD, CXCL9 correlated with KL-6 (r = 0.459) and SP-A (r = 0.274), indicating neutrophilic inflammation and epithelial injury. In ILD, higher baseline CXCL9 levels predicted subsequent improvement in lung function and declined following treatment. Cluster analysis revealed divergent CXCL9 and KL-6 trajectories linked to disease outcomes, underscoring their value as dynamic, disease-specific biomarkers. Conclusion:CXCL9 levels correlate with divergent roles in ILD and COPD. It may serve as a prognostic marker, identifying treatable inflammation in ILD and inflammatory burden in COPD.
AIM:Cholesterol uptake capacity (CUC) is a functional assessment of high-density lipoprotein (HDL) and has drawn attention for the risk stratification of atherosclerotic cardiovascular disease (ASCVD). This study evaluated the usefulness of HDL-CUC as a predictive marker for long-term ASCVD events in patients with coronary artery disease (CAD). METHODS:This retrospective observational study included 503 patients with CAD who underwent coronary revascularization. Blood was sampled from the participants within three months before or after index revascularization. The CUC was assayed using a previously reported automated system. The study population was divided into three groups according to the tertiles of CUC levels. The primary outcome was ASCVD events, which were defined as a composite of all-cause death, acute myocardial infarction, stroke, and peripheral artery disease. RESULTS:A total of 29 events were observed during the follow-up (median 2.8 years). The risk of the primary outcome in the low-CUC group was significantly higher than that in the high-CUC group (3-year incidence: low CUC 8.8% vs. high CUC 4.0%; log-rank p = 0.046). After adjusting for age and sex, the risk in the low-CUC group relative to that in the high-CUC group remained significantly high (hazard ratio 3.17, 95% confidence interval 1.05-9.54, p = 0.040). CONCLUSION:Low CUC in patients with CAD were associated with a higher risk of ASCVD events after coronary revascularization than high CUC levels. The assessment of HDL functionality measured by CUC would be useful for the risk prediction of ASCVD after coronary revascularization.